This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Authoring team

CLL usually has an insidious onset. Approximately 70 - 80% of patients are diagnosed incidentally when they are found to have lymphocytosis (1).

Rapidly progressive CLL occurs occasionally and is characterised by larger, less mature - appearing lymphocytes - "prolymphocytic" leukaemia.

When patients present with symptoms, the disease tends to have developed into a more advanced stage (2).

Typical clinical features of CLL include:

  • non-specific symptoms -
    • “B” symptoms (lethargy, weight loss, fever and night sweats) and infections
    • of anaemia and thrombocytopenia - which may be autoimmune.
  • lymphadenopathy
    • occurs in 80% of cases.
    • typically, moderate enlargement, affecting nodes in the neck, axilla and groin.
    • classically, symmetrical with non-tender, rubbery nodes
    • may have developed over a period of months or years.
  • splenomegaly
    • in 50% of cases.
  • heaptomegaly
  • skin lesions - pruritus, Herpes zoster, generalised infiltration (l'homme rouge, usually associated with pruritus), vesibullous lesions

Note:

  • B symptoms are not common but if present it might indicate that CLL has transformed into an aggressive large B-cell lymphoma (Richter’s transformation) (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.